Korro Bio, Inc. (NASDAQ:KRRO) — Market Cap & Net Worth
Market Cap & Net Worth: Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (NASDAQ:KRRO) has a market capitalization of $165.28 Million ($165.28 Million) as of July 14, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17305 globally and #4057 in its home market, demonstrating a -3.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Korro Bio, Inc.'s stock price $13.50 by its total outstanding shares 14422571 (14.42 Million). See reinvestment intensity of Korro Bio, Inc. to understand how much of operating cash flow is reinvested back into capital assets.
Korro Bio, Inc. Market Cap History: 2019 to 2026
Korro Bio, Inc.'s market capitalization history from 2019 to 2026. Data shows change from $12.64 Billion to $194.70 Million (-43.96% CAGR).
Index Memberships
Korro Bio, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.51 Trillion | 0.01% | #484 of 976 |
|
NASDAQ Composite
IXIC
|
$40.98 Trillion | 0.00% | #1707 of 3165 |
Weight: Korro Bio, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Korro Bio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Korro Bio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.07x
Korro Bio, Inc.'s market cap is 18.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $12.64 Billion | $28.95 Million | -$18.75 Million | 436.71x | N/A |
| 2020 | $25.43 Billion | $36.98 Million | -$26.51 Million | 687.51x | N/A |
| 2021 | $3.70 Billion | $14.07 Million | -$84.69 Million | 262.96x | N/A |
| 2024 | $549.07 Million | $2.27 Million | -$83.58 Million | 241.77x | N/A |
| 2025 | $115.52 Million | $6.39 Million | -$117.26 Million | 18.07x | N/A |
Competitor Companies of KRRO by Market Capitalization
Companies near Korro Bio, Inc. in the global market cap rankings as of July 14, 2026.
Key companies related to Korro Bio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #425 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #548 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #568 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.25 |
| #425 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $663.09 |
| #548 | Argen-X | BR:ARGX | $49.55 Billion | €759.60 |
| #568 | UCB SA | BR:UCB | $47.34 Billion | €235.60 |
Korro Bio, Inc. Historical Marketcap From 2019 to 2026
Between 2019 and today, Korro Bio, Inc.'s market cap moved from $12.64 Billion to $ 194.70 Million, with a yearly change of -43.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $194.70 Million | +68.54% |
| 2025 | $115.52 Million | -78.96% |
| 2024 | $549.07 Million | -20.57% |
| 2023 | $691.27 Million | -75.10% |
| 2022 | $2.78 Billion | -24.95% |
| 2021 | $3.70 Billion | -85.45% |
| 2020 | $25.43 Billion | +101.14% |
| 2019 | $12.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 14th, 2026 the market cap of Korro Bio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $165.28 Million USD |
| MoneyControl | $165.28 Million USD |
| MarketWatch | $165.28 Million USD |
| marketcap.company | $165.28 Million USD |
| Reuters | $165.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more